Radius has taken concrete steps to reduce outsized risk to our stockholders, including successfully out-licensing elacestrant, a promising breast cancer pivotal program, in August 2020.

Q1 2022 net revenue per commercial employee increased by 66% vs. Total full-time headcount has been reduced by nearly 33%, declining from ~375 to ~250 employees currently. Radius has achieved ~ 20% reduction in selling, general and administrative (SG&A) expenses since Q1 2020.

Radius has been laser-focused on costs and operating efficiency.Within the past 24 months, 90% of the management team has been changed and approximately 60% of current employees have joined the Company. Of note, this included the appointment of Mark Conley as CFO, Liz Messersmith, Ph.D., to lead RadiusвЂ™ Neuroscience Group and Danielle Holtschlag as Head of U.S. In April 2020, we recruited a new CEO, who immediately set out to rebuild the senior leadership team and strengthen Company staff.Very deliberately, and by design, under the direction of the Board of Directors and Chief Executive Officer, the Company has made significant changes and improvements to all aspects of the business, achieving a near-complete transformation of the Company from within.

THE FACTS: Significant progress since the first half of 2020 OUR THREE HIGHLY QUALIFIED AND INDEPENDENT NOMINEES ON THE BLUE PROXY CARD. These and other actions are designed to position Radius to deliver long-term shareholder value in a way that balances risk and reward within the overall context of the biopharmaceutical industry.Д¬ONTINUED PROGRESS AND SUCCESSFUL REPOSITIONING BY VOTING TODAY вЂњ FORвЂќ Under the refreshed Radius Board and new CEOвЂ™s leadership, Radius has streamlined business operations, reduced pipeline risk and dramatically improved productivity, as measured by revenue per employee. It also added five new, highly qualified directors. The Radius Board appointed a new Chairman and Chief Executive Officer. During the first half of 2020, the Company was effectively transformed through internal activism led by the Radius Board of Directors (the вЂњRadius BoardвЂќ). This is an important time for the Company. Your vote is important, and we ask for your support. EDT.ДЄt the Annual Meeting, stockholders will elect three nominees to serve as directors of the Company and represent the interests of all stockholders. (вЂњRadiusвЂќ or the вЂњCompanyвЂќ), which will be held online on July 8, 2022, at 10:00 a.m. We are writing to you today regarding the 2022 Annual Meeting of Stockholders of Radius Health, Inc. Despite the CompanyвЂ™s good faith attempts to engage with them, a group of activist stockholders continues to advocate a misinformed, short-term strategy that may not be in the interest of all stockholders the activistsвЂ™ nominees, if elected, could put at risk the CompanyвЂ™s current momentum and continued ability to execute its long-term strategy.As key members of the Radius Board, which is overseeing the CompanyвЂ™s progress and long-term value creation, this yearвЂ™s directors up for re-election are critically important to RadiusвЂ™ continued momentum, through their service on the Board as well as the direct experience and support they provide to management.Executing a balanced, integrated strategy, Radius is well positioned to realize significant long-term value from TYMLOS В® and a promising clinical pipeline, including its investigational drug elacestrant (RAD 1901) and its investigational synthetic cannabidiol oral solution with potential utilization in multiple orphan endocrine and neurological disease areas (RAD011).

Under a refreshed Board and new CEO and management team, Radius has made substantial financial, operational and strategic progress since 2020, including a ~ 20% reduction in selling, general and administrative expenses, a dramatic increase in productivity with net revenue per commercial employee increasing 66% since Q1 2020 and strengthening the CompanyвЂ™s balance sheet and capital structure for long-term value creation.In connection with the definitive proxy filing, Radius is mailing a letter to shareholders. Stockholders of record as of June 3, 2022, will be entitled to vote at the meeting. ('Radius' or the 'Company') (Nasdaq: RDUS) today announced that it has filed its definitive proxy statement with the Securities and Exchange Commission (вЂњSECвЂќ) for its upcoming Annual Meeting of Stockholders, which will be held online on July 8, 2022.

вЂ“ on the BLUE Proxy CardДetails CompanyвЂ™s Significant Progress Since 2020, Under Refreshed Board and Management TeamД«OSTON, J(GLOBE NEWSWIRE) - Radius Health, Inc. Urges Stockholders to Vote вЂњFORвЂќ RadiusвЂ™ Highly Qualified, Independent Director Nominees вЂ“ Catherine J.

Repertoire partners